Found 2555 Enz. Inhib. hit(s) with all data for entry = 31 
Affinity DataIC50: 0.0200nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.0400nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.0400nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.0600nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.0600nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.0700nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.0700nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.0800nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.0800nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.0800nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.0900nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.0900nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.0900nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.100nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.110nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.110nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.120nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.120nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.120nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.120nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [1-324](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.120nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.120nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
NOVARTIS AG
US Patent
NOVARTIS AG
US Patent
Affinity DataIC50: 0.120nMpH: 7.5 T: 2°CAssay Description:Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...More data for this Ligand-Target Pair
